Colchicine: Difference between revisions
| Line 19: | Line 19: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]:Colchicine enters breast milk, caution be used when administer in a nursing woman. | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: | ||
Revision as of 13:09, 16 June 2016
Administration
- Type: Antigout
- Dosage Forms: Capsules, Tablets
- Routes of Administration: Oral
- Common Trade Names: Colcris; Mitigare (US), Jamp-Colchicine; PMS-Colchicine (Canadian)
Adult Dosing
Gout
- Flare treatment: Initial: 1.2 mg and then 0.6 mg in an hour (maximum 1.8 mg within 1 hour). In patient receiving prophylaxis treatment wait for 12 h after flare dosing before resuming prophylaxis dose. Do not repeat treatment for at least 3 days (Canadian labelling recommendation)
- Prophylaxis Treatment: 0.6 mg twice daily (maximum 1.2 mg/day) for 3 months (without tophi) to 6 months (≥1 tophi) after reaching target serum uric acid levels [1]
- Familial Mediterranean Fever (FMF): 1.2 mg to 2.4 mg per day in 1-2 decided dose. Titrate (increase or decrease) 0.3 mg daily increment based on efficacy and adverse effects.
Pediatric Dosing
- Familial Mediterranean Fever (FMF):
- Children 4 to 6 years: 0.3 to 1.8 mg daily in 1-2 divided doses
- Children 6 to 12 years: 0.9 to 1.8 mg daily in 1-2 divided doses
- Adolescents >12 years: Adult dosing
- Gout prophylaxis/treatment: Adult dosing
Special Populations
- Pregnancy Rating:C
- Lactation risk:Colchicine enters breast milk, caution be used when administer in a nursing woman.
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Khanna D. et al.2012 ACR Guidelines for Management of Gout Part I: Systemic Non-pharmacologic and Pharmacologic Therapeutic Approach to Hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10): 1431–1446.